The effect of the Saccharomyces boulardii CNCM I-745 probiotic on the development of antibiotic-associated syndrome in children receiving systemic antibacterial therapy for lower respiratory tract infections
Authors: Gorelov А.V. ,   Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russian Federation, Usenko D.V. , Melekhina Е.V. , Muzyka A.D. , Dzotsoeva E.S. , Kremplevskaya S.P. , Krikun V.S. ,   Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russian Federation,   Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russian Federation,   Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russian Federation,   Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russian Federation,   Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russian Federation,   Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russian Federation
Published: July 2024

Objective. To evaluate the effect of the Saccharomyces boulardii CNCM I-745 probiotic on the development of antibioticassociated syndrome (AAS) in children receiving systemic antibacterial therapy for respiratory tract infections. Patients and methods. We examined 80 children patients with community-acquired pneumonia aged 1 to 14 years, who received antibacterial therapy, including in combination with the Saccharomyces boulardii CNCM I-745 probiotic (38 patients). Gastrointestinal symptoms and stool characteristics according to the Bristol scale, the condition of the skin and open mucous membranes were assessed. Results. During antibacterial therapy, symptoms of AAS developed in 60% of the patients with pneumonia. Manifestations of AAS were recorded 2 times less often in children receiving «Enterol», than other children group without probiotic correction, p < 0.05. The most common manifestations of AAS were symptoms of gastrointestinal tract damage, and along with the classic manifestations – the appearance of loose, frequent stools, patients complained of abdominal pain, bloating, stool retention, up to constipation and the appearance of “sheep” stool. Exintestinal manifestations of AAS included the development of stomatitis in 23.7% of the examined groups, while in children receiving the probiotic, stomatitis developed less frequently – 7.9% versus 38.1% (p = 0.002). Moreover, 46.1% of girls receiving antibiotic therapy developed vulvovaginitis, but its frequency in the cohort of patients receiving probiotics was significantly lower – 16.7% vs 71.4% (p = 0.001). Conclusion. The use of the probiotic drug «Enterol» containing Saccharomyces boulardii CNCM I-745 in children receiving broad-spectrum antibacterial drugs prevented the development and accelerated the regression of clinical manifestations of AAS. Key words: antibiotics, antibiotic-associated diarrhea, community-acquired pneumonia, children, microbiota, probiotics, Saccharomyces boulardii CNCM I-745, enterol